ClinicalTrials.gg
Active, not recruitingNCT05108259Updated Sep 8, 2026

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects

A Phase 1 interventional study of PBP1502 and EU-licensed Humira in Healthy Volunteers, sponsored by Prestige Biopharma Limited. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Prestige Biopharma Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502 to the European (EU) and American (US) Humira reference products, following a single subcutaneous (SC) dose of 40 mg in healthy volunteers.

Read the detailed description

This is a single centre, randomized, double-blind, three-arm, parallel group, single-dose, active comparator study, where a total of 324 healthy male and female adult volunteers - between the age of 18 and 55 years, both inclusive - will be dosed; 108 subjects per treatment group, randomly assigned to one of the 3 treatment arms.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • randomized
  • double-blind
  • phase 1
03

In context

Lead sponsor

Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects, between the age of 18 and 55 years, both inclusive (healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and heart rate measurement, 12-lead , and clinical laboratory tests prior to administration of the study drug).
  2. Subject is informed and able to understand the full nature and purpose of the study, including possible risks and side effects, and is given ample time and opportunity to read and understand this information. Subject has the ability and agrees to cooperate with the Investigator and must sign and date the written prior to performing any of the screening procedures.
  3. between 18.0 and 32.0 kg/m2, both inclusive.
  4. Subject and their partner of must agree to use a highly effective method of throughout the study and for 5 months after the administration of assigned treatment. A man is of childbearing potential if, in the opinion of the Investigator, he is sexually active. Male and female subjects and their partners who have been surgically sterilised for less than 24 weeks prior to the date of informed consent must agree to use any medically acceptable methods of contraception. Menopausal females must have experienced their last period more than 1 year prior to the date of informed consent to be classified as not of childbearing potential

Exclusion criteria

Exclusion Criteria:

  1. Subject has a medical history and/or condition including one or more of the following disease(s):

    • History and/or current presence of atopy (e.g., allergic asthma, eczematous dermatitis), known or suspected clinically relevant or allergic reactions to any of the of study drug, other murine and human proteins, or Ig products.
    • Known infection with (active or carrier of hepatitis B), , or (HIV). However, a subject with history of hepatitis B virus is allowed if resolved.
    • History of invasive systemic fungal infections (including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis, etc.) or other opportunistic infections judged by the Investigator, including local fungal infections or a history of herpes zoster.
    • History of and/or current cardiac (including class III/IV heart failure), gastrointestinal, renal, endocrine, neurologic, , hepatic haematological (including pancytopenia, aplastic anaemia, or blood dyscrasia, etc.), metabolic (including diabetes mellitus), or pulmonary disease classed as significant by the Investigator.
    • History of any .
    • Systemic or local infection, such as the risk of sepsis and/or known active inflammation within 2 months before screening.
    • Severe infections requiring hospitalisation and/or the need for IV antibiotics, within 2 months before screening.
    • Central nervous system demyelinating disease (e.g., multiple sclerosis and optic neuritis), and peripheral demyelinating disease, (e.g., Guillain-Barré syndrome)
  2. A sign of ongoing or chronic inflammation process defined as high blood concentration of C-reactive protein (CRP) (> 2.5 times the [ULN]).
  3. Subject has inadequate liver function as determined by following results:

    • Serum (ALT) and aspartate aminotransferase (AST) > 2 × ULN and
    • Total > 2 × ULN.
  4. Subject is considered to have a significant abnormal cardiac function in Investigator's discretion determined by the laboratory results.
  5. Subject underwent surgical intervention or an operation within 4 weeks prior to the administration of the study drug (Day 1) or plans to undergo a surgical procedure during the study period.
  6. Subject has active TB, latent TB (defined as a positive result for IGRA with no active lesion in examination of chest X-ray without any sign or symptom of TB), a history of TB, or had close contact with a person with active TB within 8 weeks prior to the administration of the study drug (Day 1). If the result of IGRA is indeterminate at screening, retest will be allowed only once during the screening period. If the repeated IGRA result is again indeterminate or positive, the subject will be excluded from the study. If the repeated IGRA result is negative, the subject may be included in the study.
  7. Female subject is pregnant or lactating or planning to be pregnant or to breastfeed before, during, or within 5 months after the administration of the study drug (Day 1).
  8. Male subject is planning to father a child or donate sperms within 5 months after the administration of the study drug (Day 1).
  9. Subject has received a mAb or fusion protein within 9 months prior to randomization and/or there is a confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a mAb or fusion protein, or subject is currently using a biologic (including but not limited to TNF-α blockers). Subjects with previous exposure to adalimumab are to be excluded.
  10. Subject has received treatment with a biological or agent (other than a mAb or fusion protein) within 3 months of screening.
  11. Subject used prescription (excluding hormonal ), over the counter (OTC) drugs, dietary supplements, or herbal remedies that could affect the outcome of the study within 2 weeks prior to the administration of the study drug (Day 1).
  12. Subject has undergone treatment with an drug or participated in another clinical study for healthy subject or bioequivalence test within 180 days or 5 half-lives (whichever is longer) prior to the administration of the study drug (Day 1) or plan to do so during the study.
  13. Subject received a live or within 4 weeks prior to the administration of the study drug (Day 1) or plan to do so until 6 months after Day 1.
  14. Subject has donated or lost 400 mL or more of whole blood within 8 weeks, or donated blood components within 4 weeks prior to the administration of the study drug (Day 1).
  15. Subject shows reasonable evidence of drug abuse (positive result for drug urine test and/or the opinion of the Investigator).
  16. Subject has a history or presence of regular consumption exceeding an average weekly intake of 21 units of alcohol in recent 12 weeks prior to the screening visit. One unit is equivalent to a half-pint (285 mL) of beer/lager, one measure (25 mL) of spirits, or one small glass (125 mL) of wine. Subject is unwilling to avoid use of alcohol or alcohol containing foods, medications, or beverages within 24 hours prior to admission (Day -1), and each study visit until completion of the study.
  17. Subject has smoked 10 or more cigarettes per day in the recent 12 weeks prior to the administration of the study drug (Day 1) and/or is unable to refrain from smoking up to 24 hours after the administration of the study drug.
  18. In the opinion of the Investigator, the subject is not eligible for the study participation for any reason (including clinical laboratory results) or shows evidence of a condition (e.g., psychological, or emotional problem, any disorder or resultant therapy) that is likely to invalidate an or limit the ability of the subject to comply with the protocol requirements. Subject is unable to understand the protocol requirements, instructions, study-related restrictions, or the nature, scope, and possible consequences of the clinical study; or is unable to give written informed consent or to comply fully with the protocol.
  19. Subject with confirmed COVID-19 infection by appropriate laboratory test screening and on admission.
  20. Subject is vulnerable (e.g., employees of the study centre or any other individuals involved with the conduct of the study, or immediate family members of such individuals, persons kept in prison, or other institutionalised persons by law enforcement).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    PBP1502

    Adalimumab single dose 40 mg (100 mg/mL) by SC injection via pre-filled syringe (PFS)

    Drug: PBP1502

  • Active comparator
    EU-licensed Humira

    Adalimumab single dose 40 mg (100 mg/mL) by SC injection via PFS

    Drug: EU-licensed Humira

Interventions

  • 40 mg/0.4 mL single SC injection via PFS

    Also known as: Adalimumab

  • 40 mg/0.4 mL single SC injection via PFS

    Also known as: Adalimumab

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)

    Primary endpoints were equivalence of PK between PBP1502 and reference drugs in terms of AUC0-inf. Blood samples for PK analysis were obtained pre-dose and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 192, 336, 504, 672, 1008, 1344, and 1680 hour post-dose.

    Time frame: Up to Day 71

  2. Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)

    Primary endpoints were equivalence of PK between PBP1502 and reference drugs in terms of AUC0-last. Blood samples for PK analysis were obtained pre-dose and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 192, 336, 504, 672, 1008, 1344, and 1680 hour post-dose.

    Time frame: Up to Day 71

  3. Maximum Serum Concentration (Cmax)

    Primary endpoints were equivalence of PK between PBP1502 and reference drugs in terms of Cmax. Blood samples for PK analysis were obtained pre-dose and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 192, 336, 504, 672, 1008, 1344, and 1680 hour post-dose.

    Time frame: Up to Day 71

Secondary outcomes

  1. Time to the Maximum Serum Concentration (Tmax)

    The secondary objective was to evaluate the additional PK parameters of Tmax. Blood samples for PK analysis were obtained pre-dose and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 192, 336, 504, 672, 1008, 1344, and 1680 hour post-dose.

    Time frame: Up to Day 71

  2. Terminal Elimination Half-life (t1/2)

    The secondary objective was to evaluate the additional PK parameters of t1/2. Blood samples for PK analysis were obtained pre-dose and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 192, 336, 504, 672, 1008, 1344, and 1680 hour post-dose.

    Time frame: Up to Day 71

  3. Adverse events

    Adverse events will be coded using MedDRA and grouped by system organ class and preferred term and summarised, by treatment group at the time of onset of the AE. The summary tables will present the number and percentage of total subjects and number of events, by system organ class and by preferred term. Injection related reactions will be listed and summarised by reaction using frequency counts and percentage, by treatment group.

    Time frame: Up to Day 71

  4. Anti Drug Antibodies (ADAs)

    Formation of Anti Drug Antibody will be measured through a validated assay.

    Time frame: Up to Day 71

  5. Neutralizing Antibodies (NAbs)

    Formation of neutralizing antibodies measured through a validated system

    Time frame: Up to Day 71

07

Study locations

1 site
  • Unidad de Fase I. U. Autonoma de Madrid (Clinical Trials Unit, UAM) C/ Arzobispo Morcillo 4
    Madrid, 28029, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Jun 2027, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2021
First posted
Nov 4, 2021
StartActual
Mar 30, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05108259
Lead sponsor
Prestige Biopharma Limited
Responsible party
Sponsor
First posted
Nov 4, 2021
Start date
Mar 30, 2022
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion